FDA panel wants limits on hydrocodone painkillers

Federal health advisors want new restrictions on hydrocodone, the highly addictive ingredient found in Vicodin and other widely abused prescription painkillers.

The 's panel of specialists voted to subject hydrocodone drugs to the same restrictions as narcotics like oxycodone and morphine.

Hydrocodone is sold in combination pills like Vicodin, which mixes the drug with non-addictive painkillers like acetaminophen. Doctors prescribe the medicines to treat pain from injuries, surgery, arthritis and other ailments.

Hydrocodone consistently ranks as the first or second most-abused medicine in the U.S. each year, according to the Drug Enforcement Agency.

The DEA has asked the FDA to reclassify hydrocodone as a schedule III drug, limiting which kinds of medical professionals can write a prescription and how many times it can be refilled.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US panel opposes pure hydrocodone painkiller

Dec 09, 2012

(AP)—U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone on Friday, questioning the need for a new form of one of most widely abused prescription painkillers.

Senator warns FDA on danger of newest painkillers

Jan 08, 2012

Following fatal shootings in two New York pharmacy robberies, a U.S. senator is warning that a new batch of "super painkillers" now under review could force repeats of recent violent robberies that left six people dead.

FDA cracks down on hydrocone products

Sep 29, 2007

The U.S. Food and Drug Administration says it will start taking enforcement action against companies marketing unapproved hydrocodone products.

FDA orders lower doses in prescription painkillers

Jan 13, 2011

(AP) -- Federal health regulators are limiting a key ingredient found in Vicodin, Percocet and other prescription painkillers that have been linked to thousands of cases of liver damage each year.

Recommended for you

Boxed warnings are common in novel therapeutics

14 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

15 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

16 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments